 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || Convacell / St. Petersburg Scientific Research Institute of Vaccines and Serums
Clinical, Journal: Safety and Immunogenicity of the Convacell Recombinant N Protein COVID-19 Vaccine. (Pubmed Central) - Jan 26, 2024
Convacell showed same level of immunological efficacy for single and double dose vaccination regimens, including for elderly patients. The clinical studies indicate that Convacell is safe and highly immunogenic.
- | Convacell / St. Petersburg Scientific Research Institute of Vaccines and Serums
Preclinical, Journal: Immunogenicity and In Vivo Protective Effects of Recombinant Nucleocapsid-Based SARS-CoV-2 Vaccine Convacell. (Pubmed Central) - Apr 28, 2023
Vaccinated Syrian hamsters showed reduced lung histopathology, lower virus proliferation, lower lung weight relative to the body, and faster body weight recovery. Convacell thus is shown to be effective and may augment the existing armamentarium of vaccines against COVID-19.
- | Convacell / St. Petersburg Scientific Research Institute of Vaccines and Serums
New P2/3 trial: Immunogenicity, Efficacy and Safety Trial of the Convacell Vaccine in Healthy Volunteers Aged 18 Years and Older (clinicaltrials.gov) - Feb 13, 2023
P2/3, N=16304, Active, not recruiting, Sponsor: St. Petersburg Research Institute of Vaccines and Sera
- | Convacell / St. Petersburg Scientific Research Institute of Vaccines and Serums
Trial completion, Trial completion date: Study of the Immunogenicity, Safety and Tolerability of the Convacell Vaccine. (clinicaltrials.gov) - Jan 19, 2023
P1/2, N=155, Completed, Sponsor: St. Petersburg Research Institute of Vaccines and Sera
Convacell thus is shown to be effective and may augment the existing armamentarium of vaccines against COVID-19. Active, not recruiting --> Completed | Trial completion date: May 2022 --> Dec 2022
- | Convacell / St. Petersburg Scientific Research Institute of Vaccines and Serums
New P1/2 trial: Study of the Immunogenicity, Safety and Tolerability of the Convacell Vaccine. (clinicaltrials.gov) - Dec 13, 2021
P1/2, N=155, Active, not recruiting, Sponsor: St. Petersburg Research Institute of Vaccines and Sera